{
  "id": "topic3",
  "title": "Topic 3: Organ System Disorders Part A - Pulmonary, Cardiovascular & Renal/Genital",
  "description": "[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.",
  "difficulty": "Intermediate",
  "tags": [
    "cardiovascular",
    "respiratory",
    "cardiac",
    "pulmonary"
  ],
  "estimatedTime": 17,
  "importance": 1,
  "sections": [
    {
      "id": "quick-navigation",
      "title": "Quick Navigation",
      "content": "**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Cancer Genetics](topic2-cancer-genetics.md)** | **[‚û°Ô∏è Next: Neurological Disorders](topic4-neurological-developmental.md)**\n\n### üìã Table of Contents\n- [üéØ Learning Objectives](#-learning-objectives)\n- [ü´Å Pulmonary Disorders](#-pulmonary-disorders)\n  - [Cystic Fibrosis (CF) ‚≠ê‚≠ê‚≠ê](#cystic-fibrosis-cf-)\n  - [Œ±1-Antitrypsin Deficiency ‚≠ê‚≠ê](#Œ±1-antitrypsin-deficiency-)\n- [‚ù§Ô∏è Cardiovascular Disorders](#Ô∏è-cardiovascular-disorders)\n  - [Hypertrophic Cardiomyopathy (HCM) ‚≠ê‚≠ê‚≠ê](#hypertrophic-cardiomyopathy-hcm-)\n  - [Long QT Syndrome (LQTS) ‚≠ê‚≠ê‚≠ê](#long-qt-syndrome-lqts-)\n  - [Dilated Cardiomyopathy (DCM) ‚≠ê‚≠ê](#dilated-cardiomyopathy-dcm-)\n  - [Additional Cardiovascular Conditions](#additional-cardiovascular-conditions)\n- [ü´ò Renal/Genital Disorders](#-renalgenital-disorders)\n  - [Polycystic Kidney Disease ‚≠ê‚≠ê‚≠ê](#polycystic-kidney-disease-)\n  - [Alport Syndrome ‚≠ê‚≠ê](#alport-syndrome-)\n  - [Disorders of Sex Development](#disorders-of-sex-development)\n- [üß† Study Tips & Mnemonics](#-study-tips--mnemonics)\n- [üìù High-Yield Facts Summary](#-high-yield-facts-summary)\n- [üéØ Practice Questions](#-practice-questions)\n- [üèÅ Topic 3 Completion Checklist](#-topic-3-completion-checklist)\n\n### üîç Quick Condition Lookup\n| Condition | Gene(s) | Key Features | Inheritance | Prevalence |\n|-----------|---------|--------------|-------------|------------|\n| **Cystic Fibrosis** | CFTR | Pulmonary insufficiency, CBAVD, ‚Üë sweat Cl‚Åª | AR | 1/3,200 |\n| **Œ±1-Antitrypsin Deficiency** | SERPINA1 | Early emphysema, liver disease | Co-dominant | 1/2,500 |\n| **Hypertrophic Cardiomyopathy** | MYH7, MYBPC3 | Thick cardiac muscle, sudden death risk | AD | 1/500 |\n| **Long QT Syndrome** | KCNQ1, KCNH2, SCN5A | Prolonged QT, syncope, triggers | AD | 1/2,500 |\n| **ADPKD** | PKD1, PKD2 | Bilateral renal cysts, hypertension | AD | 1/1,000 |\n| **Alport Syndrome** | COL4A5, COL4A3/4 | Progressive nephritis, hearing loss | X-linked/AR | 1/50,000 |\n| **AIS** | AR | 46,XY with female external genitalia | X-linked | 1/20,000 |\n\n---",
      "importance": 1
    },
    {
      "id": "learning-objectives",
      "title": "Learning Objectives",
      "content": "By the end of this topic, you should be able to:\n\n1. **Explain** CFTR mutation classes and their clinical implications in cystic fibrosis\n2. **Apply** cystic fibrosis carrier screening guidelines and interpret residual risks\n3. **Distinguish** between different types of cardiomyopathies and their genetic causes\n4. **Recognize** clinical features and genetic testing for Long QT syndrome variants\n5. **Compare** autosomal dominant vs autosomal recessive polycystic kidney disease\n6. **Understand** disorders of sex development and their genetic mechanisms\n7. **Describe** Œ±1-antitrypsin deficiency inheritance and phenotype-genotype correlations\n8. **Analyze** family history patterns for organ system genetic disorders\n\n---",
      "importance": 1
    },
    {
      "id": "pulmonary-disorders",
      "title": "\udec1 PULMONARY DISORDERS",
      "content": "### Cystic Fibrosis (CF) ‚≠ê‚≠ê‚≠ê\n**Most Important Pulmonary Genetic Disorder - Study This First!**\n\n#### üîë Key Features (Top 3)\n1. **Pulmonary insufficiency** - chronic respiratory infections, thick mucus\n2. **CBAVD** - congenital bilateral absence of vas deferens (male infertility)\n3. **Elevated sweat chloride** - diagnostic hallmark (>60 mEq/L)\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n**Pulmonary:**\n- Thick, sticky mucus ‚Üí chronic bacterial infections\n- Pseudomonas aeruginosa colonization\n- Progressive lung damage and fibrosis\n- Chronic cough, wheezing, shortness of breath\n\n**Gastrointestinal:**\n- Pancreatic insufficiency ‚Üí malabsorption, FTT\n- Meconium ileus (10-15% of newborns)\n- CF-related diabetes (CFRD)\n- Liver disease, gallstones\n\n**Reproductive:**\n- Male infertility due to CBAVD (>95%)\n- Female fertility reduced but possible\n\n**Other:**\n- Salt-wasting, dehydration\n- Nasal polyps, sinusitis\n- Clubbing of fingers/toes\n\n</details>\n\n<details>\n<summary><strong>üß¨ CFTR Mutation Classes</strong> (Click to expand)</summary>\n\n**Class 1 - Protein Production Defects:**\n- Nonsense, frameshift, splice mutations\n- No functional CFTR produced\n- **Severe phenotype**\n\n**Class 2 - Protein Processing Defects:**\n- ŒîF508 (most common worldwide mutation)\n- Protein misfolded, degraded before reaching membrane\n- **Severe phenotype**\n\n**Class 3 - Gating Defects:**\n- G551D (responds to ivacaftor)\n- Protein reaches membrane but doesn't open properly\n- **Severe phenotype**\n\n**Class 4 - Conduction Defects:**\n- R117H (with poly T tract)\n- Reduced chloride conductance\n- **Milder phenotype**\n\n**Class 5 - Insufficient Protein:**\n- Splice mutations affecting protein amount\n- **Variable phenotype**\n\n**Class 6 - Decreased Stability:**\n- Protein reaches membrane but unstable\n- **Variable phenotype**\n\n</details>\n\n<details>\n<summary><strong>üß™ CFTR Modifiers - R117H and Poly T Tract</strong> (Click to expand)</summary>\n\n**Critical Board Concept:**\n- **R117H variant** + poly T tract = variable penetrance\n- **Poly T tract**: 5T, 7T, or 9T repeats\n- **TG tract**: Adjacent sequence affecting splicing\n\n**Clinical Implications:**\n- **R117H + 5T**: Pancreatic sufficient CF, CBAVD\n- **R117H + 7T**: Variable phenotype\n- **R117H + 9T**: Mild or asymptomatic\n- **5T alone** (without R117H): Can cause CBAVD\n\n</details>\n\n<details>\n<summary><strong>üìä Carrier Screening Guidelines</strong> (Click to expand)</summary>\n\n**ACOG Recommendations:**\n- **Offer to all women** considering pregnancy or currently pregnant\n- **Pan-ethnic screening** recommended\n- **23-mutation panel** minimum (population-specific)\n- **Extended panels** available but not required for screening\n\n**Indications for Screening:**\n- Family history of CF\n- Ultrasound findings: echogenic bowel, dilated bowel\n- Partner with CF or CBAVD\n- Consanguinity\n\n**Important Screening Notes:**\n- **Full CFTR sequencing NOT recommended** for routine screening\n- **R117H requires poly T testing** when detected\n- **Population-specific residual risks** vary significantly\n\n</details>\n\n<details>\n<summary><strong>üß™ Diagnostic Testing</strong> (Click to expand)</summary>\n\n**Gold Standard:**\n- **Sweat chloride test**: >60 mEq/L diagnostic\n- **Intermediate**: 30-59 mEq/L (repeat testing needed)\n- **Normal**: <30 mEq/L\n\n**Molecular Testing:**\n- Confirm CFTR mutations\n- Guide therapy selection (e.g., ivacaftor for G551D)\n\n**Newborn Screening:**\n- Immunoreactive trypsinogen (IRT)\n- DNA analysis if elevated IRT\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Inheritance**: Autosomal recessive\n- **Prevalence**: 1/3,200 (varies by ethnicity)\n- **Carrier frequency**: ~1/25 in Northern European populations\n- **Mechanism**: Defective CFTR ‚Üí abnormal chloride transport ‚Üí thick mucus\n\n</details>\n\n#### üíé Board Pearls\n- CF is most common lethal AR disorder in Caucasians\n- CFTR classes 1-3 = severe, classes 4-6 = milder\n- ŒîF508 accounts for ~70% of CF alleles worldwide\n- CBAVD can be isolated (mild CFTR variants) or part of CF spectrum\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Œ±1-Antitrypsin Deficiency](#Œ±1-antitrypsin-deficiency-)**\n\n---\n\n### Œ±1-Antitrypsin Deficiency ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Emphysema** - particularly lower lobe, early onset\n2. **Liver dysfunction** - jaundice, cirrhosis, hepatocellular carcinoma risk\n3. **Co-dominant inheritance** - both alleles contribute to phenotype\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n**Pulmonary:**\n- Early-onset emphysema (especially if smoker)\n- Lower lobe predominance (unusual for smoking-related)\n- Chronic obstructive pulmonary disease (COPD)\n\n**Hepatic:**\n- Childhood: Neonatal jaundice, liver disease\n- Adults: Cirrhosis, fibrosis, hepatocellular carcinoma risk\n- Œ±1-AT accumulation in hepatocytes\n\n**Other:**\n- Panniculitis (inflammation of subcutaneous fat)\n- Increased infection susceptibility\n\n</details>\n\n<details>\n<summary><strong>üß¨ Molecular Genetics</strong> (Click to expand)</summary>\n\n**SERPINA1 Gene Variants:**\n- **M allele**: Normal (wild-type)\n- **S allele**: Moderately reduced Œ±1-AT levels\n- **Z allele**: Severely reduced Œ±1-AT levels\n\n**Phenotype Severity (most to least severe):**\n1. **ZZ**: Severe deficiency, high risk lung and liver disease\n2. **SZ**: Moderate deficiency, increased lung disease risk (especially smokers)\n3. **SS**: Mild deficiency, usually asymptomatic\n4. **MZ**: Slightly increased risk\n5. **MS**: Normal protection\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Inheritance**: Autosomal co-dominant\n- **Prevalence**: 1/1,500-2,500 (European populations)\n- **Carrier frequency**: 1/25 (European populations)\n- **Z allele frequency**: Highest in Northern/Western Europe\n\n</details>\n\n#### üíé Board Pearls\n- One of most common metabolic disorders in Europeans\n- Smoking dramatically increases lung disease risk in deficient individuals\n- Liver disease can occur without lung involvement\n- \"Co-dominant\" = both alleles affect phenotype\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Cardiovascular Disorders](#Ô∏è-cardiovascular-disorders)**\n\n---",
      "importance": 1
    },
    {
      "id": "cardiovascular-disorders",
      "title": "‚ù§ CARDIOVASCULAR DISORDERS",
      "content": "### Hypertrophic Cardiomyopathy (HCM) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Thickened cardiac muscle** - interventricular septum most common\n2. **Sudden cardiac death risk** - especially young athletes\n3. **Sarcomere gene mutations** - contractile protein defects\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n**Symptoms:**\n- Chest pain, shortness of breath\n- Syncope (especially with exercise)\n- Palpitations, fatigue\n- Heart failure symptoms\n\n**Physical Findings:**\n- Systolic murmur (increases with Valsalva)\n- Left ventricular outflow tract obstruction\n- Arrhythmias (atrial fibrillation common)\n\n**Complications:**\n- Sudden cardiac death\n- Heart failure\n- Stroke/thromboembolism\n- Infective endocarditis\n\n</details>\n\n<details>\n<summary><strong>üß¨ Molecular Genetics</strong> (Click to expand)</summary>\n\n**Major Genes:**\n- **MYH7** (Œ≤-myosin heavy chain): 40% of cases\n- **MYBPC3** (myosin-binding protein C): 40% of cases\n- **TNNT2** (troponin T): 5% of cases\n- **TNNI3** (troponin I): 5% of cases\n- **TPM1** (tropomyosin): 2% of cases\n\n**Inheritance Patterns:**\n- **Autosomal dominant**: 95%\n- **Autosomal recessive**: 5% (severe, early onset)\n- **Variable expressivity and penetrance**\n\n</details>\n\n<details>\n<summary><strong>üìà Statistics & Management</strong> (Click to expand)</summary>\n\n- **Prevalence**: 1/500 (most common inherited cardiomyopathy)\n- **Age of onset**: Any age, including infants\n- **Family history**: Present in 60% with positive family history, 30% without\n- **Genetic testing yield**: 30-60% depending on family history\n\n</details>\n\n#### üíé Board Pearls\n- Leading cause of sudden death in young athletes\n- Obstruction increases with decreased preload (Valsalva, standing)\n- Genetic testing recommended for all HCM patients\n- Screen first-degree relatives with echo and ECG\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Long QT Syndrome](#long-qt-syndrome-lqts-)**\n\n---\n\n### Long QT Syndrome (LQTS) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Prolonged QT interval** - >440 ms (males), >460 ms (females)\n2. **Syncope with triggers** - exercise, emotion, loud sounds\n3. **Sudden cardiac death** - torsades de pointes ‚Üí ventricular fibrillation\n\n<details>\n<summary><strong>üè• Clinical Features & Triggers</strong> (Click to expand)</summary>\n\n**Symptoms:**\n- Syncope (especially during physical/emotional stress)\n- Palpitations, dizziness\n- Sudden cardiac death\n- May be asymptomatic\n\n**Type-Specific Triggers:**\n- **LQT1**: Exercise (especially swimming)\n- **LQT2**: Emotional stress, loud sounds (alarm clocks)\n- **LQT3**: Rest/sleep, bradycardia\n\n</details>\n\n<details>\n<summary><strong>üß¨ Major LQTS Types</strong> (Click to expand)</summary>\n\n**LQT1 (35% of cases):**\n- **Gene**: KCNQ1 (potassium channel)\n- **Trigger**: Exercise, swimming\n- **Response**: Œ≤-blockers effective\n\n**LQT2 (25-40% of cases):**\n- **Gene**: KCNH2 (potassium channel)\n- **Trigger**: Auditory stimuli, emotion\n- **Response**: Œ≤-blockers, avoid QT-prolonging drugs\n\n**LQT3 (10% of cases):**\n- **Gene**: SCN5A (sodium channel)\n- **Trigger**: Sleep, rest, bradycardia\n- **Response**: Œ≤-blockers less effective, consider pacemaker\n\n</details>\n\n<details>\n<summary><strong>üé≠ LQTS Syndromes</strong> (Click to expand)</summary>\n\n**Romano-Ward Syndrome:**\n- **Autosomal dominant LQTS**\n- **No extracardiac features**\n- **Most common form**\n\n**Jervell and Lange-Nielsen Syndrome:**\n- **Autosomal recessive LQTS**\n- **Sensorineural hearing loss**\n- **More severe cardiac phenotype**\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Inheritance**: Autosomal dominant (Romano-Ward), AR (Jervell-Lange-Nielsen)\n- **Prevalence**: 1/2,500\n- **Penetrance**: Variable, incomplete\n- **De novo**: ~1%\n\n</details>\n\n#### üíé Board Pearls\n- Cardiac events most common ages 10-20 years\n- 20% of families have no detectable mutation\n- Œ≤-blockers first-line therapy for LQT1 and LQT2\n- Genetic testing guides therapy and family screening\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Dilated Cardiomyopathy](#dilated-cardiomyopathy-dcm-)**\n\n---\n\n### Dilated Cardiomyopathy (DCM) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Left ventricular enlargement** - dilated, thin-walled\n2. **Systolic dysfunction** - ejection fraction <50%\n3. **Heart failure symptoms** - shortness of breath, fatigue\n\n#### üè• Clinical Features\n- **Symptoms**: Fatigue, shortness of breath, fluid retention\n- **Physical**: Displaced apical impulse, S3 gallop, murmurs\n- **Complications**: Heart failure, arrhythmias, sudden death, stroke\n\n#### üß¨ Molecular Genetics\n- **>30 genes identified**: TTN, SCN5A, LMNA most common\n- **Genetic overlap**: Some genes cause both DCM and HCM\n- **Inheritance**: Usually autosomal dominant; X-linked, mitochondrial rare\n\n#### üìà Statistics\n- **Prevalence**: 1/1,000\n- **Most common indication for heart transplant**\n- **Genetic testing yield**: 20-40%\n\n---\n\n### Additional Cardiovascular Conditions\n\n#### Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) ‚≠ê‚≠ê\n- **Key Features**: Right ventricle affected, sudden death in athletes\n- **Genes**: Desmosome genes (PKP2, DSC2, DSG2, DSP, JUP)\n- **Inheritance**: AD with low penetrance\n- **Prevalence**: 1/1,000-1,250\n- **Male predominance**: 2.7:1\n\n#### Brugada Syndrome ‚≠ê‚≠ê\n- **Key Features**: Sudden death at rest/sleep, normal ECG often\n- **Gene**: SCN5A (sodium channel)\n- **Demographics**: More common in Asian populations\n- **Inheritance**: AD with low penetrance\n\n#### Holt-Oram Syndrome ‚≠ê\n- **Key Features**: Upper limb malformations + CHD\n- **Gene**: TBX5\n- **CHD**: ASD, VSD, conduction defects (75%)\n- **Limb**: Carpal bone abnormalities (100%)\n\n#### Alagille Syndrome ‚≠ê\n- **Key Features**: Bile duct paucity, butterfly vertebrae, peripheral pulmonary stenosis\n- **Genes**: JAG1 (94-96%), NOTCH2 (1-2%)\n- **Inheritance**: AD, 50-70% de novo\n\n---",
      "importance": 1
    },
    {
      "id": "renalgenital-disorders",
      "title": "\uded8 RENAL/GENITAL DISORDERS",
      "content": "### Polycystic Kidney Disease ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Bilateral renal cysts** - progressive enlargement\n2. **Hypertension** - early and common complication\n3. **Family history** - AD form shows clear inheritance pattern\n\n#### üè• Clinical Features\n\n**Renal:**\n- Multiple bilateral cysts\n- Progressive kidney enlargement\n- Chronic kidney disease ‚Üí ESRD\n- Hypertension, hematuria, UTIs, kidney stones\n\n**Extrarenal:**\n- **Hepatic cysts** (>90% of patients)\n- **Intracranial aneurysms** (5x general population risk)\n- **Cardiac**: Mitral valve prolapse, aortic root dilatation\n- **GI**: Colonic diverticular disease\n\n#### üìä ADPKD vs ARPKD\n\n**Autosomal Dominant PKD (ADPKD):**\n- **Genes**: PKD1 (78%), PKD2, GANAB, DNAJB11\n- **Age of onset**: 30s-40s (symptoms), cysts present from birth\n- **PKD1**: More severe, ESRD average age 70\n- **PKD2**: Less severe, later onset\n- **Inheritance**: AD with high penetrance\n\n**Autosomal Recessive PKD (ARPKD):**\n- **Genes**: PKHD1, DZIP1L\n- **Age of onset**: Birth/early infancy\n- **Features**: Enlarged echogenic kidneys, oligohydramnios, Potter sequence\n- **Prognosis**: 30% die within first year, >50% progress to ESRD in first decade\n\n#### üìà Inheritance & Statistics\n- **ADPKD prevalence**: 1/400-1,000\n- **ARPKD prevalence**: 1/20,000\n- **Penetrance**: Nearly 100% by age 60 (ADPKD)\n\n#### üíé Board Pearls\n- ADPKD is most common inherited kidney disease\n- Screen for intracranial aneurysms if family history or high-risk occupation\n- Prenatal diagnosis available but variable expressivity makes counseling complex\n\n---\n\n### Alport Syndrome ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Progressive nephritis** - hematuria ‚Üí proteinuria ‚Üí ESRD\n2. **Sensorineural hearing loss** - bilateral, progressive\n3. **Ocular abnormalities** - anterior lenticonus (pathognomonic)\n\n#### üè• Clinical Features\n\n**Renal:**\n- Microscopic hematuria (earliest sign)\n- Progressive proteinuria\n- Chronic kidney disease ‚Üí ESRD\n\n**Auditory:**\n- Bilateral sensorineural hearing loss\n- Progressive, usually post-lingual\n\n**Ocular:**\n- **Anterior lenticonus** (pathognomonic)\n- Retinal flecks, corneal dystrophy\n\n**Other:**\n- Diffuse leiomyomatosis (rare)\n\n#### üß¨ Molecular Genetics\n\n**X-linked (85%):**\n- **Gene**: COL4A5\n- **Males**: Severe disease, ESRD by age 30\n- **Females**: Variable (X-inactivation), may only have hematuria\n\n**Autosomal Recessive (10-15%):**\n- **Genes**: COL4A3, COL4A4\n- **Phenotype**: Similar to X-linked males\n\n**Autosomal Dominant (rare):**\n- **Genes**: COL4A3, COL4A4\n- **Phenotype**: Milder, later onset\n\n#### üìà Inheritance & Statistics\n- **Prevalence**: 1/50,000\n- **Gene function**: Type IV collagen (basement membrane)\n- **De novo mutations**: 10-15% in X-linked\n\n---\n\n### Disorders of Sex Development\n\n#### Androgen Insensitivity Syndrome (AIS) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **46,XY karyotype** with female external genitalia\n2. **Androgen receptor defects** - inability to respond to androgens\n3. **Infertility** and cancer risk in undescended testes\n\n#### üè• Clinical Features\n\n**Complete AIS:**\n- Female external genitalia\n- Absent/minimal pubic and axillary hair\n- Primary amenorrhea\n- Undescended testes (cancer risk)\n- Normal female psychosocial development\n\n**Partial AIS:**\n- Ambiguous genitalia\n- Variable degree of virilization\n- May have micropenis, hypospadias\n\n#### üß¨ Molecular Genetics\n- **Gene**: AR (androgen receptor)\n- **Inheritance**: X-linked recessive\n- **Mechanism**: Defective androgen receptor ‚Üí inability to respond to testosterone/DHT\n\n#### üìà Statistics & Management\n- **Prevalence**: 2-5/100,000\n- **Management**: Gonadectomy after puberty (cancer risk), hormone replacement therapy\n\n---\n\n#### Y Chromosome Infertility ‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Male infertility** - azoospermia or severe oligospermia\n2. **AZF deletions** - azoospermia factor regions on Y chromosome\n3. **De novo occurrence** - usually not inherited\n\n#### üß¨ Molecular Mechanism\n- **AZF regions**: AZFa, AZFb, AZFc on Y chromosome\n- **Function**: Essential for spermatogenesis\n- **Inheritance**: De novo deletions, occasionally inherited from mosaic fathers\n\n#### üìà Statistics\n- **Prevalence**: 1/2,000-3,000 males\n- **Clinical**: Normal external genitalia, primary infertility\n\n---",
      "importance": 1
    },
    {
      "id": "study-tips-mnemonics",
      "title": "Study Tips & Mnemonics",
      "content": "<details>\n<summary><strong>ü´Å CF Memory Aids</strong> (Click to expand)</summary>\n\n**CFTR Mutation Classes**:\n- **\"Production, Processing, Gating, Conduction\"** (Classes 1-4)\n- **\"Severe classes 1-2-3, Milder 4-5-6\"**\n\n**CF Clinical Features**:\n- **\"Salty, Sweet, Sticky, Sterile\"** - Salty sweat, Sweet taste when kissed, Sticky mucus, Sterile (infertile) males\n\n</details>\n\n<details>\n<summary><strong>‚ù§Ô∏è Cardiomyopathy Memory Aid</strong> (Click to expand)</summary>\n\n**\"HCM = Huge, DCM = Dilated, ARVC = Right\"**\n- **HCM**: Hypertrophic = thick walls\n- **DCM**: Dilated = big chambers, weak\n- **ARVC**: Right ventricle primarily affected\n\n</details>\n\n<details>\n<summary><strong>‚ö° Long QT Triggers</strong> (Click to expand)</summary>\n\n**\"1-2-3, Exercise-Emotion-Sleep\"**\n- **LQT1**: Exercise (especially swimming)\n- **LQT2**: Emotion, loud sounds\n- **LQT3**: Sleep, rest\n\n</details>\n\n<details>\n<summary><strong>ü´ò PKD Memory Aid</strong> (Click to expand)</summary>\n\n**\"AD = Adult, AR = infantile\"**\n- **ADPKD**: Adult onset, better prognosis\n- **ARPKD**: infAntile onset, poor prognosis\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: High-Yield Facts](#-high-yield-facts-summary)**\n\n---",
      "importance": 1
    },
    {
      "id": "highyield-facts-summary",
      "title": "High-Yield Facts Summary",
      "content": "<details>\n<summary><strong>üéØ Must-Know Genetics</strong> (Click to expand)</summary>\n\n- **CF**: Most common lethal AR disorder in Caucasians, ŒîF508 most common\n- **HCM**: Most common inherited cardiomyopathy (1/500)\n- **LQTS**: 1/2,500, genotype predicts triggers and therapy\n- **ADPKD**: Most common inherited kidney disease\n\n</details>\n\n<details>\n<summary><strong>üß™ Testing Essentials</strong> (Click to expand)</summary>\n\n- **CF carrier screening**: Offer to all women, 23-mutation panel minimum\n- **Cardiac genetic testing**: Family history crucial, guides screening\n- **Sweat chloride**: Gold standard for CF diagnosis\n- **Echocardiogram + ECG**: Screening for inherited cardiomyopathies\n\n</details>\n\n<details>\n<summary><strong>üîó Clinical Correlations</strong> (Click to expand)</summary>\n\n- **CFTR modifiers**: R117H + poly T determines phenotype\n- **Œ±1-AT**: Co-dominant inheritance, smoking greatly increases risk\n- **LQTS**: Trigger-specific therapy based on genotype\n- **AIS**: Gonadectomy needed due to cancer risk\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Practice Questions](#-practice-questions)**\n\n---",
      "importance": 1
    },
    {
      "id": "practice-questions",
      "title": "Practice Questions",
      "content": "> **üìù Study Tip**: Try answering these questions before clicking for the answer. These mirror actual board exam question styles.\n\n### Question 1\nA couple undergoes CF carrier screening. The woman tests positive for ŒîF508, and the man tests positive for R117H. Additional testing shows the man has R117H with 5T. What is the most likely phenotype if they have an affected child?\n\n**A)** Classic cystic fibrosis with pancreatic insufficiency  \n**B)** Pancreatic sufficient CF with mild lung disease  \n**C)** Isolated CBAVD  \n**D)** Normal phenotype\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B) Pancreatic sufficient CF with mild lung disease**\n\nR117H with 5T typically causes pancreatic sufficient CF. When combined with a severe mutation like ŒîF508, the phenotype is determined by the milder allele, resulting in pancreatic sufficient CF with variable lung involvement.\n</details>\n\n### Question 2\nA 16-year-old competitive swimmer experiences recurrent syncope during practice. ECG shows QTc of 480 ms. Family history reveals a maternal uncle who died suddenly while swimming at age 20. What is the most likely genetic finding?\n\n**A)** KCNQ1 mutation (LQT1)  \n**B)** KCNH2 mutation (LQT2)  \n**C)** SCN5A mutation (LQT3)  \n**D)** RYR2 mutation (CPVT)\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A) KCNQ1 mutation (LQT1)**\n\nThe combination of syncope with swimming (exercise trigger), prolonged QT interval, and family history of sudden death while swimming is highly suggestive of LQT1 (KCNQ1 mutations), which characteristically causes symptoms during exercise, especially swimming.\n</details>\n\n### Question 3\nA 35-year-old man with emphysema has a ZZ genotype for Œ±1-antitrypsin deficiency. His sister wants to know her risk. She has never smoked and is asymptomatic. What is her most likely genotype and recommendation?\n\n**A)** ZZ genotype; she will definitely develop lung disease  \n**B)** MZ genotype; no increased risk  \n**C)** SZ or ZZ genotype; genetic testing recommended  \n**D)** MM genotype; reassurance only\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: C) SZ or ZZ genotype; genetic testing recommended**\n\nSince her brother has ZZ genotype, both parents are at least MZ carriers. Her possible genotypes are MM, MZ, SZ, or ZZ. Given the significant health implications and available interventions (smoking cessation, monitoring), genetic testing is appropriate to determine her exact risk.\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Completion Checklist](#-topic-3-completion-checklist)**\n\n---",
      "importance": 1
    },
    {
      "id": "topic-3-completion-checklist",
      "title": "Topic 3 Completion Checklist",
      "content": "### ‚úÖ Knowledge Mastery\n- [ ] Understand CFTR mutation classes and their clinical implications\n- [ ] Know CF carrier screening guidelines and when to offer testing\n- [ ] Can distinguish between different cardiomyopathies and their genetics\n- [ ] Understand LQTS genotype-phenotype correlations and triggers\n- [ ] Know the difference between ADPKD and ARPKD\n- [ ] Recognize features of disorders of sex development\n- [ ] Understand Œ±1-antitrypsin co-dominant inheritance\n\n### üéØ Practice & Review\n- [ ] Completed all practice questions successfully\n- [ ] Reviewed mnemonics and memory aids\n- [ ] Can recall prevalences and inheritance patterns\n- [ ] Understand genotype-phenotype correlations\n\n### üîÑ Self-Assessment\n- [ ] Confident explaining CFTR modifier effects\n- [ ] Can distinguish between cardiomyopathy types\n- [ ] Ready to move to next topic\n\n---",
      "importance": 1
    },
    {
      "id": "navigation",
      "title": "\udd17 Navigation",
      "content": "**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Cancer Genetics](topic2-cancer-genetics.md)** | **[‚û°Ô∏è Next Topic: Neurological Disorders](topic4-neurological-developmental.md)**\n\n---\n\n**üïí Study Time Recommendation:** 8-10 hours  \n**üóìÔ∏è Review Schedule:** Review this topic after completing Topic 5\n\n**üèÜ Completion Status:** Topic 3 of 6 complete",
      "importance": 1
    }
  ],
  "objectives": [],
  "sectionCount": 10,
  "rawContent": "# Topic 3: Organ System Disorders Part A - Pulmonary, Cardiovascular & Renal/Genital\n\n## üìñ Quick Navigation\n\n**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Cancer Genetics](topic2-cancer-genetics.md)** | **[‚û°Ô∏è Next: Neurological Disorders](topic4-neurological-developmental.md)**\n\n### üìã Table of Contents\n- [üéØ Learning Objectives](#-learning-objectives)\n- [ü´Å Pulmonary Disorders](#-pulmonary-disorders)\n  - [Cystic Fibrosis (CF) ‚≠ê‚≠ê‚≠ê](#cystic-fibrosis-cf-)\n  - [Œ±1-Antitrypsin Deficiency ‚≠ê‚≠ê](#Œ±1-antitrypsin-deficiency-)\n- [‚ù§Ô∏è Cardiovascular Disorders](#Ô∏è-cardiovascular-disorders)\n  - [Hypertrophic Cardiomyopathy (HCM) ‚≠ê‚≠ê‚≠ê](#hypertrophic-cardiomyopathy-hcm-)\n  - [Long QT Syndrome (LQTS) ‚≠ê‚≠ê‚≠ê](#long-qt-syndrome-lqts-)\n  - [Dilated Cardiomyopathy (DCM) ‚≠ê‚≠ê](#dilated-cardiomyopathy-dcm-)\n  - [Additional Cardiovascular Conditions](#additional-cardiovascular-conditions)\n- [ü´ò Renal/Genital Disorders](#-renalgenital-disorders)\n  - [Polycystic Kidney Disease ‚≠ê‚≠ê‚≠ê](#polycystic-kidney-disease-)\n  - [Alport Syndrome ‚≠ê‚≠ê](#alport-syndrome-)\n  - [Disorders of Sex Development](#disorders-of-sex-development)\n- [üß† Study Tips & Mnemonics](#-study-tips--mnemonics)\n- [üìù High-Yield Facts Summary](#-high-yield-facts-summary)\n- [üéØ Practice Questions](#-practice-questions)\n- [üèÅ Topic 3 Completion Checklist](#-topic-3-completion-checklist)\n\n### üîç Quick Condition Lookup\n| Condition | Gene(s) | Key Features | Inheritance | Prevalence |\n|-----------|---------|--------------|-------------|------------|\n| **Cystic Fibrosis** | CFTR | Pulmonary insufficiency, CBAVD, ‚Üë sweat Cl‚Åª | AR | 1/3,200 |\n| **Œ±1-Antitrypsin Deficiency** | SERPINA1 | Early emphysema, liver disease | Co-dominant | 1/2,500 |\n| **Hypertrophic Cardiomyopathy** | MYH7, MYBPC3 | Thick cardiac muscle, sudden death risk | AD | 1/500 |\n| **Long QT Syndrome** | KCNQ1, KCNH2, SCN5A | Prolonged QT, syncope, triggers | AD | 1/2,500 |\n| **ADPKD** | PKD1, PKD2 | Bilateral renal cysts, hypertension | AD | 1/1,000 |\n| **Alport Syndrome** | COL4A5, COL4A3/4 | Progressive nephritis, hearing loss | X-linked/AR | 1/50,000 |\n| **AIS** | AR | 46,XY with female external genitalia | X-linked | 1/20,000 |\n\n---\n\n## üéØ Learning Objectives\n\nBy the end of this topic, you should be able to:\n\n1. **Explain** CFTR mutation classes and their clinical implications in cystic fibrosis\n2. **Apply** cystic fibrosis carrier screening guidelines and interpret residual risks\n3. **Distinguish** between different types of cardiomyopathies and their genetic causes\n4. **Recognize** clinical features and genetic testing for Long QT syndrome variants\n5. **Compare** autosomal dominant vs autosomal recessive polycystic kidney disease\n6. **Understand** disorders of sex development and their genetic mechanisms\n7. **Describe** Œ±1-antitrypsin deficiency inheritance and phenotype-genotype correlations\n8. **Analyze** family history patterns for organ system genetic disorders\n\n---\n\n## ü´Å PULMONARY DISORDERS\n\n### Cystic Fibrosis (CF) ‚≠ê‚≠ê‚≠ê\n**Most Important Pulmonary Genetic Disorder - Study This First!**\n\n#### üîë Key Features (Top 3)\n1. **Pulmonary insufficiency** - chronic respiratory infections, thick mucus\n2. **CBAVD** - congenital bilateral absence of vas deferens (male infertility)\n3. **Elevated sweat chloride** - diagnostic hallmark (>60 mEq/L)\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n**Pulmonary:**\n- Thick, sticky mucus ‚Üí chronic bacterial infections\n- Pseudomonas aeruginosa colonization\n- Progressive lung damage and fibrosis\n- Chronic cough, wheezing, shortness of breath\n\n**Gastrointestinal:**\n- Pancreatic insufficiency ‚Üí malabsorption, FTT\n- Meconium ileus (10-15% of newborns)\n- CF-related diabetes (CFRD)\n- Liver disease, gallstones\n\n**Reproductive:**\n- Male infertility due to CBAVD (>95%)\n- Female fertility reduced but possible\n\n**Other:**\n- Salt-wasting, dehydration\n- Nasal polyps, sinusitis\n- Clubbing of fingers/toes\n\n</details>\n\n<details>\n<summary><strong>üß¨ CFTR Mutation Classes</strong> (Click to expand)</summary>\n\n**Class 1 - Protein Production Defects:**\n- Nonsense, frameshift, splice mutations\n- No functional CFTR produced\n- **Severe phenotype**\n\n**Class 2 - Protein Processing Defects:**\n- ŒîF508 (most common worldwide mutation)\n- Protein misfolded, degraded before reaching membrane\n- **Severe phenotype**\n\n**Class 3 - Gating Defects:**\n- G551D (responds to ivacaftor)\n- Protein reaches membrane but doesn't open properly\n- **Severe phenotype**\n\n**Class 4 - Conduction Defects:**\n- R117H (with poly T tract)\n- Reduced chloride conductance\n- **Milder phenotype**\n\n**Class 5 - Insufficient Protein:**\n- Splice mutations affecting protein amount\n- **Variable phenotype**\n\n**Class 6 - Decreased Stability:**\n- Protein reaches membrane but unstable\n- **Variable phenotype**\n\n</details>\n\n<details>\n<summary><strong>üß™ CFTR Modifiers - R117H and Poly T Tract</strong> (Click to expand)</summary>\n\n**Critical Board Concept:**\n- **R117H variant** + poly T tract = variable penetrance\n- **Poly T tract**: 5T, 7T, or 9T repeats\n- **TG tract**: Adjacent sequence affecting splicing\n\n**Clinical Implications:**\n- **R117H + 5T**: Pancreatic sufficient CF, CBAVD\n- **R117H + 7T**: Variable phenotype\n- **R117H + 9T**: Mild or asymptomatic\n- **5T alone** (without R117H): Can cause CBAVD\n\n</details>\n\n<details>\n<summary><strong>üìä Carrier Screening Guidelines</strong> (Click to expand)</summary>\n\n**ACOG Recommendations:**\n- **Offer to all women** considering pregnancy or currently pregnant\n- **Pan-ethnic screening** recommended\n- **23-mutation panel** minimum (population-specific)\n- **Extended panels** available but not required for screening\n\n**Indications for Screening:**\n- Family history of CF\n- Ultrasound findings: echogenic bowel, dilated bowel\n- Partner with CF or CBAVD\n- Consanguinity\n\n**Important Screening Notes:**\n- **Full CFTR sequencing NOT recommended** for routine screening\n- **R117H requires poly T testing** when detected\n- **Population-specific residual risks** vary significantly\n\n</details>\n\n<details>\n<summary><strong>üß™ Diagnostic Testing</strong> (Click to expand)</summary>\n\n**Gold Standard:**\n- **Sweat chloride test**: >60 mEq/L diagnostic\n- **Intermediate**: 30-59 mEq/L (repeat testing needed)\n- **Normal**: <30 mEq/L\n\n**Molecular Testing:**\n- Confirm CFTR mutations\n- Guide therapy selection (e.g., ivacaftor for G551D)\n\n**Newborn Screening:**\n- Immunoreactive trypsinogen (IRT)\n- DNA analysis if elevated IRT\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Inheritance**: Autosomal recessive\n- **Prevalence**: 1/3,200 (varies by ethnicity)\n- **Carrier frequency**: ~1/25 in Northern European populations\n- **Mechanism**: Defective CFTR ‚Üí abnormal chloride transport ‚Üí thick mucus\n\n</details>\n\n#### üíé Board Pearls\n- CF is most common lethal AR disorder in Caucasians\n- CFTR classes 1-3 = severe, classes 4-6 = milder\n- ŒîF508 accounts for ~70% of CF alleles worldwide\n- CBAVD can be isolated (mild CFTR variants) or part of CF spectrum\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Œ±1-Antitrypsin Deficiency](#Œ±1-antitrypsin-deficiency-)**\n\n---\n\n### Œ±1-Antitrypsin Deficiency ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Emphysema** - particularly lower lobe, early onset\n2. **Liver dysfunction** - jaundice, cirrhosis, hepatocellular carcinoma risk\n3. **Co-dominant inheritance** - both alleles contribute to phenotype\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n**Pulmonary:**\n- Early-onset emphysema (especially if smoker)\n- Lower lobe predominance (unusual for smoking-related)\n- Chronic obstructive pulmonary disease (COPD)\n\n**Hepatic:**\n- Childhood: Neonatal jaundice, liver disease\n- Adults: Cirrhosis, fibrosis, hepatocellular carcinoma risk\n- Œ±1-AT accumulation in hepatocytes\n\n**Other:**\n- Panniculitis (inflammation of subcutaneous fat)\n- Increased infection susceptibility\n\n</details>\n\n<details>\n<summary><strong>üß¨ Molecular Genetics</strong> (Click to expand)</summary>\n\n**SERPINA1 Gene Variants:**\n- **M allele**: Normal (wild-type)\n- **S allele**: Moderately reduced Œ±1-AT levels\n- **Z allele**: Severely reduced Œ±1-AT levels\n\n**Phenotype Severity (most to least severe):**\n1. **ZZ**: Severe deficiency, high risk lung and liver disease\n2. **SZ**: Moderate deficiency, increased lung disease risk (especially smokers)\n3. **SS**: Mild deficiency, usually asymptomatic\n4. **MZ**: Slightly increased risk\n5. **MS**: Normal protection\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Inheritance**: Autosomal co-dominant\n- **Prevalence**: 1/1,500-2,500 (European populations)\n- **Carrier frequency**: 1/25 (European populations)\n- **Z allele frequency**: Highest in Northern/Western Europe\n\n</details>\n\n#### üíé Board Pearls\n- One of most common metabolic disorders in Europeans\n- Smoking dramatically increases lung disease risk in deficient individuals\n- Liver disease can occur without lung involvement\n- \"Co-dominant\" = both alleles affect phenotype\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Cardiovascular Disorders](#Ô∏è-cardiovascular-disorders)**\n\n---\n\n## ‚ù§Ô∏è CARDIOVASCULAR DISORDERS\n\n### Hypertrophic Cardiomyopathy (HCM) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Thickened cardiac muscle** - interventricular septum most common\n2. **Sudden cardiac death risk** - especially young athletes\n3. **Sarcomere gene mutations** - contractile protein defects\n\n<details>\n<summary><strong>üè• Clinical Features</strong> (Click to expand)</summary>\n\n**Symptoms:**\n- Chest pain, shortness of breath\n- Syncope (especially with exercise)\n- Palpitations, fatigue\n- Heart failure symptoms\n\n**Physical Findings:**\n- Systolic murmur (increases with Valsalva)\n- Left ventricular outflow tract obstruction\n- Arrhythmias (atrial fibrillation common)\n\n**Complications:**\n- Sudden cardiac death\n- Heart failure\n- Stroke/thromboembolism\n- Infective endocarditis\n\n</details>\n\n<details>\n<summary><strong>üß¨ Molecular Genetics</strong> (Click to expand)</summary>\n\n**Major Genes:**\n- **MYH7** (Œ≤-myosin heavy chain): 40% of cases\n- **MYBPC3** (myosin-binding protein C): 40% of cases\n- **TNNT2** (troponin T): 5% of cases\n- **TNNI3** (troponin I): 5% of cases\n- **TPM1** (tropomyosin): 2% of cases\n\n**Inheritance Patterns:**\n- **Autosomal dominant**: 95%\n- **Autosomal recessive**: 5% (severe, early onset)\n- **Variable expressivity and penetrance**\n\n</details>\n\n<details>\n<summary><strong>üìà Statistics & Management</strong> (Click to expand)</summary>\n\n- **Prevalence**: 1/500 (most common inherited cardiomyopathy)\n- **Age of onset**: Any age, including infants\n- **Family history**: Present in 60% with positive family history, 30% without\n- **Genetic testing yield**: 30-60% depending on family history\n\n</details>\n\n#### üíé Board Pearls\n- Leading cause of sudden death in young athletes\n- Obstruction increases with decreased preload (Valsalva, standing)\n- Genetic testing recommended for all HCM patients\n- Screen first-degree relatives with echo and ECG\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Long QT Syndrome](#long-qt-syndrome-lqts-)**\n\n---\n\n### Long QT Syndrome (LQTS) ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Prolonged QT interval** - >440 ms (males), >460 ms (females)\n2. **Syncope with triggers** - exercise, emotion, loud sounds\n3. **Sudden cardiac death** - torsades de pointes ‚Üí ventricular fibrillation\n\n<details>\n<summary><strong>üè• Clinical Features & Triggers</strong> (Click to expand)</summary>\n\n**Symptoms:**\n- Syncope (especially during physical/emotional stress)\n- Palpitations, dizziness\n- Sudden cardiac death\n- May be asymptomatic\n\n**Type-Specific Triggers:**\n- **LQT1**: Exercise (especially swimming)\n- **LQT2**: Emotional stress, loud sounds (alarm clocks)\n- **LQT3**: Rest/sleep, bradycardia\n\n</details>\n\n<details>\n<summary><strong>üß¨ Major LQTS Types</strong> (Click to expand)</summary>\n\n**LQT1 (35% of cases):**\n- **Gene**: KCNQ1 (potassium channel)\n- **Trigger**: Exercise, swimming\n- **Response**: Œ≤-blockers effective\n\n**LQT2 (25-40% of cases):**\n- **Gene**: KCNH2 (potassium channel)\n- **Trigger**: Auditory stimuli, emotion\n- **Response**: Œ≤-blockers, avoid QT-prolonging drugs\n\n**LQT3 (10% of cases):**\n- **Gene**: SCN5A (sodium channel)\n- **Trigger**: Sleep, rest, bradycardia\n- **Response**: Œ≤-blockers less effective, consider pacemaker\n\n</details>\n\n<details>\n<summary><strong>üé≠ LQTS Syndromes</strong> (Click to expand)</summary>\n\n**Romano-Ward Syndrome:**\n- **Autosomal dominant LQTS**\n- **No extracardiac features**\n- **Most common form**\n\n**Jervell and Lange-Nielsen Syndrome:**\n- **Autosomal recessive LQTS**\n- **Sensorineural hearing loss**\n- **More severe cardiac phenotype**\n\n</details>\n\n<details>\n<summary><strong>üìà Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Inheritance**: Autosomal dominant (Romano-Ward), AR (Jervell-Lange-Nielsen)\n- **Prevalence**: 1/2,500\n- **Penetrance**: Variable, incomplete\n- **De novo**: ~1%\n\n</details>\n\n#### üíé Board Pearls\n- Cardiac events most common ages 10-20 years\n- 20% of families have no detectable mutation\n- Œ≤-blockers first-line therapy for LQT1 and LQT2\n- Genetic testing guides therapy and family screening\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Dilated Cardiomyopathy](#dilated-cardiomyopathy-dcm-)**\n\n---\n\n### Dilated Cardiomyopathy (DCM) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Left ventricular enlargement** - dilated, thin-walled\n2. **Systolic dysfunction** - ejection fraction <50%\n3. **Heart failure symptoms** - shortness of breath, fatigue\n\n#### üè• Clinical Features\n- **Symptoms**: Fatigue, shortness of breath, fluid retention\n- **Physical**: Displaced apical impulse, S3 gallop, murmurs\n- **Complications**: Heart failure, arrhythmias, sudden death, stroke\n\n#### üß¨ Molecular Genetics\n- **>30 genes identified**: TTN, SCN5A, LMNA most common\n- **Genetic overlap**: Some genes cause both DCM and HCM\n- **Inheritance**: Usually autosomal dominant; X-linked, mitochondrial rare\n\n#### üìà Statistics\n- **Prevalence**: 1/1,000\n- **Most common indication for heart transplant**\n- **Genetic testing yield**: 20-40%\n\n---\n\n### Additional Cardiovascular Conditions\n\n#### Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) ‚≠ê‚≠ê\n- **Key Features**: Right ventricle affected, sudden death in athletes\n- **Genes**: Desmosome genes (PKP2, DSC2, DSG2, DSP, JUP)\n- **Inheritance**: AD with low penetrance\n- **Prevalence**: 1/1,000-1,250\n- **Male predominance**: 2.7:1\n\n#### Brugada Syndrome ‚≠ê‚≠ê\n- **Key Features**: Sudden death at rest/sleep, normal ECG often\n- **Gene**: SCN5A (sodium channel)\n- **Demographics**: More common in Asian populations\n- **Inheritance**: AD with low penetrance\n\n#### Holt-Oram Syndrome ‚≠ê\n- **Key Features**: Upper limb malformations + CHD\n- **Gene**: TBX5\n- **CHD**: ASD, VSD, conduction defects (75%)\n- **Limb**: Carpal bone abnormalities (100%)\n\n#### Alagille Syndrome ‚≠ê\n- **Key Features**: Bile duct paucity, butterfly vertebrae, peripheral pulmonary stenosis\n- **Genes**: JAG1 (94-96%), NOTCH2 (1-2%)\n- **Inheritance**: AD, 50-70% de novo\n\n---\n\n## ü´ò RENAL/GENITAL DISORDERS\n\n### Polycystic Kidney Disease ‚≠ê‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Bilateral renal cysts** - progressive enlargement\n2. **Hypertension** - early and common complication\n3. **Family history** - AD form shows clear inheritance pattern\n\n#### üè• Clinical Features\n\n**Renal:**\n- Multiple bilateral cysts\n- Progressive kidney enlargement\n- Chronic kidney disease ‚Üí ESRD\n- Hypertension, hematuria, UTIs, kidney stones\n\n**Extrarenal:**\n- **Hepatic cysts** (>90% of patients)\n- **Intracranial aneurysms** (5x general population risk)\n- **Cardiac**: Mitral valve prolapse, aortic root dilatation\n- **GI**: Colonic diverticular disease\n\n#### üìä ADPKD vs ARPKD\n\n**Autosomal Dominant PKD (ADPKD):**\n- **Genes**: PKD1 (78%), PKD2, GANAB, DNAJB11\n- **Age of onset**: 30s-40s (symptoms), cysts present from birth\n- **PKD1**: More severe, ESRD average age 70\n- **PKD2**: Less severe, later onset\n- **Inheritance**: AD with high penetrance\n\n**Autosomal Recessive PKD (ARPKD):**\n- **Genes**: PKHD1, DZIP1L\n- **Age of onset**: Birth/early infancy\n- **Features**: Enlarged echogenic kidneys, oligohydramnios, Potter sequence\n- **Prognosis**: 30% die within first year, >50% progress to ESRD in first decade\n\n#### üìà Inheritance & Statistics\n- **ADPKD prevalence**: 1/400-1,000\n- **ARPKD prevalence**: 1/20,000\n- **Penetrance**: Nearly 100% by age 60 (ADPKD)\n\n#### üíé Board Pearls\n- ADPKD is most common inherited kidney disease\n- Screen for intracranial aneurysms if family history or high-risk occupation\n- Prenatal diagnosis available but variable expressivity makes counseling complex\n\n---\n\n### Alport Syndrome ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Progressive nephritis** - hematuria ‚Üí proteinuria ‚Üí ESRD\n2. **Sensorineural hearing loss** - bilateral, progressive\n3. **Ocular abnormalities** - anterior lenticonus (pathognomonic)\n\n#### üè• Clinical Features\n\n**Renal:**\n- Microscopic hematuria (earliest sign)\n- Progressive proteinuria\n- Chronic kidney disease ‚Üí ESRD\n\n**Auditory:**\n- Bilateral sensorineural hearing loss\n- Progressive, usually post-lingual\n\n**Ocular:**\n- **Anterior lenticonus** (pathognomonic)\n- Retinal flecks, corneal dystrophy\n\n**Other:**\n- Diffuse leiomyomatosis (rare)\n\n#### üß¨ Molecular Genetics\n\n**X-linked (85%):**\n- **Gene**: COL4A5\n- **Males**: Severe disease, ESRD by age 30\n- **Females**: Variable (X-inactivation), may only have hematuria\n\n**Autosomal Recessive (10-15%):**\n- **Genes**: COL4A3, COL4A4\n- **Phenotype**: Similar to X-linked males\n\n**Autosomal Dominant (rare):**\n- **Genes**: COL4A3, COL4A4\n- **Phenotype**: Milder, later onset\n\n#### üìà Inheritance & Statistics\n- **Prevalence**: 1/50,000\n- **Gene function**: Type IV collagen (basement membrane)\n- **De novo mutations**: 10-15% in X-linked\n\n---\n\n### Disorders of Sex Development\n\n#### Androgen Insensitivity Syndrome (AIS) ‚≠ê‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **46,XY karyotype** with female external genitalia\n2. **Androgen receptor defects** - inability to respond to androgens\n3. **Infertility** and cancer risk in undescended testes\n\n#### üè• Clinical Features\n\n**Complete AIS:**\n- Female external genitalia\n- Absent/minimal pubic and axillary hair\n- Primary amenorrhea\n- Undescended testes (cancer risk)\n- Normal female psychosocial development\n\n**Partial AIS:**\n- Ambiguous genitalia\n- Variable degree of virilization\n- May have micropenis, hypospadias\n\n#### üß¨ Molecular Genetics\n- **Gene**: AR (androgen receptor)\n- **Inheritance**: X-linked recessive\n- **Mechanism**: Defective androgen receptor ‚Üí inability to respond to testosterone/DHT\n\n#### üìà Statistics & Management\n- **Prevalence**: 2-5/100,000\n- **Management**: Gonadectomy after puberty (cancer risk), hormone replacement therapy\n\n---\n\n#### Y Chromosome Infertility ‚≠ê\n\n#### üîë Key Features (Top 3)\n1. **Male infertility** - azoospermia or severe oligospermia\n2. **AZF deletions** - azoospermia factor regions on Y chromosome\n3. **De novo occurrence** - usually not inherited\n\n#### üß¨ Molecular Mechanism\n- **AZF regions**: AZFa, AZFb, AZFc on Y chromosome\n- **Function**: Essential for spermatogenesis\n- **Inheritance**: De novo deletions, occasionally inherited from mosaic fathers\n\n#### üìà Statistics\n- **Prevalence**: 1/2,000-3,000 males\n- **Clinical**: Normal external genitalia, primary infertility\n\n---\n\n## üß† Study Tips & Mnemonics\n\n<details>\n<summary><strong>ü´Å CF Memory Aids</strong> (Click to expand)</summary>\n\n**CFTR Mutation Classes**:\n- **\"Production, Processing, Gating, Conduction\"** (Classes 1-4)\n- **\"Severe classes 1-2-3, Milder 4-5-6\"**\n\n**CF Clinical Features**:\n- **\"Salty, Sweet, Sticky, Sterile\"** - Salty sweat, Sweet taste when kissed, Sticky mucus, Sterile (infertile) males\n\n</details>\n\n<details>\n<summary><strong>‚ù§Ô∏è Cardiomyopathy Memory Aid</strong> (Click to expand)</summary>\n\n**\"HCM = Huge, DCM = Dilated, ARVC = Right\"**\n- **HCM**: Hypertrophic = thick walls\n- **DCM**: Dilated = big chambers, weak\n- **ARVC**: Right ventricle primarily affected\n\n</details>\n\n<details>\n<summary><strong>‚ö° Long QT Triggers</strong> (Click to expand)</summary>\n\n**\"1-2-3, Exercise-Emotion-Sleep\"**\n- **LQT1**: Exercise (especially swimming)\n- **LQT2**: Emotion, loud sounds\n- **LQT3**: Sleep, rest\n\n</details>\n\n<details>\n<summary><strong>ü´ò PKD Memory Aid</strong> (Click to expand)</summary>\n\n**\"AD = Adult, AR = infantile\"**\n- **ADPKD**: Adult onset, better prognosis\n- **ARPKD**: infAntile onset, poor prognosis\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: High-Yield Facts](#-high-yield-facts-summary)**\n\n---\n\n## üìù High-Yield Facts Summary\n\n<details>\n<summary><strong>üéØ Must-Know Genetics</strong> (Click to expand)</summary>\n\n- **CF**: Most common lethal AR disorder in Caucasians, ŒîF508 most common\n- **HCM**: Most common inherited cardiomyopathy (1/500)\n- **LQTS**: 1/2,500, genotype predicts triggers and therapy\n- **ADPKD**: Most common inherited kidney disease\n\n</details>\n\n<details>\n<summary><strong>üß™ Testing Essentials</strong> (Click to expand)</summary>\n\n- **CF carrier screening**: Offer to all women, 23-mutation panel minimum\n- **Cardiac genetic testing**: Family history crucial, guides screening\n- **Sweat chloride**: Gold standard for CF diagnosis\n- **Echocardiogram + ECG**: Screening for inherited cardiomyopathies\n\n</details>\n\n<details>\n<summary><strong>üîó Clinical Correlations</strong> (Click to expand)</summary>\n\n- **CFTR modifiers**: R117H + poly T determines phenotype\n- **Œ±1-AT**: Co-dominant inheritance, smoking greatly increases risk\n- **LQTS**: Trigger-specific therapy based on genotype\n- **AIS**: Gonadectomy needed due to cancer risk\n\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Practice Questions](#-practice-questions)**\n\n---\n\n## üéØ Practice Questions\n\n> **üìù Study Tip**: Try answering these questions before clicking for the answer. These mirror actual board exam question styles.\n\n### Question 1\nA couple undergoes CF carrier screening. The woman tests positive for ŒîF508, and the man tests positive for R117H. Additional testing shows the man has R117H with 5T. What is the most likely phenotype if they have an affected child?\n\n**A)** Classic cystic fibrosis with pancreatic insufficiency  \n**B)** Pancreatic sufficient CF with mild lung disease  \n**C)** Isolated CBAVD  \n**D)** Normal phenotype\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B) Pancreatic sufficient CF with mild lung disease**\n\nR117H with 5T typically causes pancreatic sufficient CF. When combined with a severe mutation like ŒîF508, the phenotype is determined by the milder allele, resulting in pancreatic sufficient CF with variable lung involvement.\n</details>\n\n### Question 2\nA 16-year-old competitive swimmer experiences recurrent syncope during practice. ECG shows QTc of 480 ms. Family history reveals a maternal uncle who died suddenly while swimming at age 20. What is the most likely genetic finding?\n\n**A)** KCNQ1 mutation (LQT1)  \n**B)** KCNH2 mutation (LQT2)  \n**C)** SCN5A mutation (LQT3)  \n**D)** RYR2 mutation (CPVT)\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A) KCNQ1 mutation (LQT1)**\n\nThe combination of syncope with swimming (exercise trigger), prolonged QT interval, and family history of sudden death while swimming is highly suggestive of LQT1 (KCNQ1 mutations), which characteristically causes symptoms during exercise, especially swimming.\n</details>\n\n### Question 3\nA 35-year-old man with emphysema has a ZZ genotype for Œ±1-antitrypsin deficiency. His sister wants to know her risk. She has never smoked and is asymptomatic. What is her most likely genotype and recommendation?\n\n**A)** ZZ genotype; she will definitely develop lung disease  \n**B)** MZ genotype; no increased risk  \n**C)** SZ or ZZ genotype; genetic testing recommended  \n**D)** MM genotype; reassurance only\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: C) SZ or ZZ genotype; genetic testing recommended**\n\nSince her brother has ZZ genotype, both parents are at least MZ carriers. Her possible genotypes are MM, MZ, SZ, or ZZ. Given the significant health implications and available interventions (smoking cessation, monitoring), genetic testing is appropriate to determine her exact risk.\n</details>\n\n**[‚¨ÜÔ∏è Back to Top](#-quick-navigation)** | **[‚û°Ô∏è Next: Completion Checklist](#-topic-3-completion-checklist)**\n\n---\n\n## üèÅ Topic 3 Completion Checklist\n\n### ‚úÖ Knowledge Mastery\n- [ ] Understand CFTR mutation classes and their clinical implications\n- [ ] Know CF carrier screening guidelines and when to offer testing\n- [ ] Can distinguish between different cardiomyopathies and their genetics\n- [ ] Understand LQTS genotype-phenotype correlations and triggers\n- [ ] Know the difference between ADPKD and ARPKD\n- [ ] Recognize features of disorders of sex development\n- [ ] Understand Œ±1-antitrypsin co-dominant inheritance\n\n### üéØ Practice & Review\n- [ ] Completed all practice questions successfully\n- [ ] Reviewed mnemonics and memory aids\n- [ ] Can recall prevalences and inheritance patterns\n- [ ] Understand genotype-phenotype correlations\n\n### üîÑ Self-Assessment\n- [ ] Confident explaining CFTR modifier effects\n- [ ] Can distinguish between cardiomyopathy types\n- [ ] Ready to move to next topic\n\n---\n\n## üîó Navigation\n\n**[‚¨ÜÔ∏è Back to Master Index](study-guide-master-index.md)** | **[‚¨ÖÔ∏è Previous: Cancer Genetics](topic2-cancer-genetics.md)** | **[‚û°Ô∏è Next Topic: Neurological Disorders](topic4-neurological-developmental.md)**\n\n---\n\n**üïí Study Time Recommendation:** 8-10 hours  \n**üóìÔ∏è Review Schedule:** Review this topic after completing Topic 5\n\n**üèÜ Completion Status:** Topic 3 of 6 complete"
}